×
About 14,370 results

ALLMedicine™ Ankylosing Spondylitis Center

Research & Reviews  3,655 results

Risk of Severe COVID-19 Outcomes Among Patients with Immune-Mediated Inflammatory Disea...
https://doi.org/10.1007/s12325-022-02293-0
Advances in Therapy; Yue X, Ye Y et. al.

Sep 26th, 2022 - There are concerns that patients in an immunocompromised state may be at risk for increased coronavirus disease 2019 (COVID-19) severity. The aim of this study was to describe the characteristics of patients with COVID-19 and immune-mediated infla...

Multidisciplinary Team Led by Joint Surgeons to Rapidly Identify Spondyloarthritis.
https://www.ncbi.nlm.nih.gov/pubmed/36150014
Alternative Therapies in Health and Medicine; Wang D, Yu X et. al.

Sep 24th, 2022 - Spondyloarthritis (SpA) is a group of chronic, inflammatory, rheumatic diseases of which axial SpA and peripheral SpA are the two main types. Patients that predominantly have manifestations of axSpA may have additional peripheral-arthritis symptom...

A Study of CC-99677 in Participants With Active Ankylosing Spondylitis
https://clinicaltrials.gov/ct2/show/NCT04947579

Sep 23rd, 2022 - This study is designed to learn about response to CC-99677 treatment by measuring signs and symptoms of Ankylosing Spondylitis (AS), objective measures of disease activity, quality of life assessments, pharmacokinetics, safety, and tolerability ov...

ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis
https://clinicaltrials.gov/ct2/show/NCT04795141

Sep 22nd, 2022 - ABY-035-204 is a double-blind, randomized, parallel-group, placebo-controlled study. The primary objective is to estimate the relationship between different dose regimens of ABY-035 and clinical response as assessed by Assessment of Spondyloarthri...

Understanding sex-related differences in healthcare utilisation among patients with inf...
https://doi.org/10.1136/ard-2022-222779
Annals of the Rheumatic Diseases; Tarannum S, Widdifield J et. al.

Sep 22nd, 2022 - Our aim was to compare patterns of musculoskeletal-related healthcare utilisation between male and female patients before and after the diagnosis of inflammatory arthritis (IA). We used Ontario administrative health data to create three inception ...

see more →

Guidelines  11 results

2019 Update of the American College of Rheumatology/Spondylitis Association of America/...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764882
Arthritis & Rheumatology (Hoboken, N.J.); Ward MM, Deodhar A et. al.

Aug 23rd, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). We conducted updated systematic literature reviews for 20 clinical questions on pharmacologi...

Responsible, Safe, and Effective Use of Antithrombotics and Anticoagulants in Patients ...
https://www.ncbi.nlm.nih.gov/pubmed/30717501
Pain Physician; Kaye AD, Manchikanti L et. al.

Feb 6th, 2019 - Interventional pain management involves diagnosis and treatment of chronic pain. This specialty utilizes minimally invasive procedures to target therapeutics to the central nervous system and the spinal column. A subset of patients encountered in ...

The effectiveness, safety, and economic evaluation of Korean medicine for unexplained i...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779787
Medicine

Mar 6th, 2018 - Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the ...

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.
https://doi.org/10.1136/annrheumdis-2016-210770
Annals of the Rheumatic Diseases; van der Heijde D, Ramiro S et. al.

Jan 15th, 2017 - To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with...

EULAR recommendations for cardiovascular disease risk management in patients with rheum...
https://doi.org/10.1136/annrheumdis-2016-209775
Annals of the Rheumatic Diseases; Agca R, Heslinga SC et. al.

Oct 5th, 2016 - Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommend...

see more →

Drugs  913 results see all →

Clinicaltrials.gov  380 results

A Study of CC-99677 in Participants With Active Ankylosing Spondylitis
https://clinicaltrials.gov/ct2/show/NCT04947579

Sep 23rd, 2022 - This study is designed to learn about response to CC-99677 treatment by measuring signs and symptoms of Ankylosing Spondylitis (AS), objective measures of disease activity, quality of life assessments, pharmacokinetics, safety, and tolerability ov...

ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis
https://clinicaltrials.gov/ct2/show/NCT04795141

Sep 22nd, 2022 - ABY-035-204 is a double-blind, randomized, parallel-group, placebo-controlled study. The primary objective is to estimate the relationship between different dose regimens of ABY-035 and clinical response as assessed by Assessment of Spondyloarthri...

A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis
https://clinicaltrials.gov/ct2/show/NCT03355573

Sep 19th, 2022 - This is a study to assess the long term safety and tolerability of bimekizumab in subjects with ankylosing spondylitis

Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)
https://clinicaltrials.gov/ct2/show/NCT03259074

Sep 15th, 2022 - The purpose of this study is to demonstrate the impact of secukinumab on progression of structural damage in the spine, as measured by the mSASSS in patients with AS.

Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries
https://clinicaltrials.gov/ct2/show/NCT02281747

Sep 15th, 2022 - Major orthopedic procedures, including total joint replacement and spine surgeries, are among the most common procedures in the population. Learning about how often these surgeries are performed can give indications of whether the treatment of art...

see more →

News  779 results

Isolated axial PsA and eventual development of peripheral disease
https://www.mdedge.com/rheumatology/article/257905/psoriatic-arthritis/isolated-axial-psa-and-eventual-development

Sep 16th, 2022 - Key clinical point: Patients with isolated axial psoriatic arthritis (PsA) had a better functional status than those with both axial and peripheral disease. Human leucocyte antigen (HLA)-B*27 positivity was associated with isolated axial PsA and p.

Spondyloarthritis disease activity measurement with ASDAS not influenced by gender
https://www.mdedge.com/rheumatology/article/257845/ankylosing-spondylitis/spondyloarthritis-disease-activity-measurement
Becky McCall

Sep 14th, 2022 - GHENT, BELGIUM – The Ankylosing Spondylitis Disease Activity Score (ASDAS) should be the preferred tool for disease activity assessment in patients with axial spondyloarthritis (axSpA) because it is not influenced by gender, according to new data.

Spondyloarthritis Disease Activity Measurement With ASDAS Not Influenced by Gender
https://www.medscape.com/viewarticle/980800

Sep 14th, 2022 - GHENT, Belgium – The Ankylosing Spondylitis Disease Activity Score (ASDAS) should be the preferred tool for disease activity assessment in patients with axial spondyloarthritis (axSpA) because it is not influenced by gender, according to new data ...

COX-2, TNF inhibitor combo appear to have limited role in reducing axSpA spinal damage progression
https://www.mdedge.com/rheumatology/article/257712/ankylosing-spondylitis/cox-2-tnf-inhibitor-combo-appear-have-limited
Becky McCall

Sep 12th, 2022 - GHENT, BELGIUM – A strong numerical signal suggests the addition of a selective cyclooxygenase-2 (COX-2) inhibitor to a tumor necrosis factor (TNF) inhibitor can reduce spinal radiographic progression in patients with active radiographic axial spo.

Limited Role for COX-2, TNFi in Reducing AxSpA Progression
https://www.medscape.com/viewarticle/980664

Sep 12th, 2022 - GHENT, BELGIUM — A strong numerical signal suggests the addition of a selective cyclooxygenase-2 (COX-2) inhibitor to a tumor necrosis factor (TNF) inhibitor can reduce spinal radiographic progression in patients with active radiographic axial spo...

see more →

Patient Education  10 results see all →